Literature DB >> 15999432

Medicare program; competitive acquisition of outpatient drugs and biologicals under Part B. Interim final rule with comment period.

.   

Abstract

This interim final rule with comment period implements provisions of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 that require the implementation of a competitive acquisition program for certain Medicare Part B drugs not paid on a cost or prospective payment system basis. Beginning January 1, 2006, physicians will generally be given a choice between obtaining these drugs from vendors selected through a competitive bidding process or directly purchasing these drugs and being paid under the average sales price system.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15999432

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  1 in total

1.  Orphan drug pricing and payer management in the United States: are we approaching the tipping point?

Authors:  Rebecca Hyde; Diana Dobrovolny
Journal:  Am Health Drug Benefits       Date:  2010-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.